
Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom improvements but do not address anaemia, an adverse prognostic factor. Momelotinib, an inhibitor of ACVR1/ALK2, JAK1 and JAK2, demonstrated activity against anaemia, symptoms, and splenomegaly in phase 3 SIMPLIFY trials. In addition, week 24 TI response in JAKi-naïve, momelotinib-randomized patients was associated with improved OS in univariate and multivariate analyses. These findings underscore the importance of achieving or maintaining TI in myelofibrosis, supporting the clinical relevance of momelotinib’s pro-erythropoietic mechanism of action and potentially informing treatment decision-making.
Like
Save
Share